U.S. markets open in 6 hours 39 minutes
  • S&P Futures

    3,855.00
    +10.00 (+0.26%)
     
  • Dow Futures

    31,151.00
    +55.00 (+0.18%)
     
  • Nasdaq Futures

    13,357.25
    +63.00 (+0.47%)
     
  • Russell 2000 Futures

    2,159.80
    +2.10 (+0.10%)
     
  • Crude Oil

    53.28
    +0.04 (+0.08%)
     
  • Gold

    1,867.90
    +1.40 (+0.08%)
     
  • Silver

    25.89
    +0.12 (+0.46%)
     
  • EUR/USD

    1.2136
    +0.0021 (+0.17%)
     
  • 10-Yr Bond

    1.0900
    0.0000 (0.00%)
     
  • Vix

    21.58
    -1.66 (-7.14%)
     
  • GBP/USD

    1.3704
    +0.0049 (+0.36%)
     
  • USD/JPY

    103.4700
    -0.1000 (-0.10%)
     
  • BTC-USD

    34,845.33
    +182.72 (+0.53%)
     
  • CMC Crypto 200

    689.52
    -11.09 (-1.58%)
     
  • FTSE 100

    6,740.39
    +27.44 (+0.41%)
     
  • Nikkei 225

    28,756.86
    +233.60 (+0.82%)
     

Global Blood Therapeutics to seek to expand label for sickle cell treatment

Carl O'Donnell
·1 min read

By Carl O'Donnell

June 8 (Reuters) - Global Blood Therapeutics Inc said on Monday it plans to ask U.S. regulators to greenlight the use of its sickle cell treatment, Oxbryta, in children between ages 4 and 11, expanding on an earlier approval for patients 12 and over.

The South San Francisco, California-based company recently met with the U.S. Food and Drug Administration and plans to submit a formal application for an expanded approval next year, it said in a statement. The company is continuing to collect data supporting Oxbryta's safety and effectiveness in children between 4 and 11 but existing data is strong, Chief Executive Ted Love told Reuters in an interview. (Reporting by Carl O'Donnell Editing by Leslie Adler)